MDH2 and prostate carcinoma: In spite of mutations in the MDH2 gene are observed in several cancers, including uterine cancer, prostate cancer, pheochromocytoma, and other paragangliomas, MDH2 overexpression was observed in doxorubicin-resistant uterine and prostate cancer cells and may contribute to drug resistance in disease models [18].